Role of non-major histocompatibility complex antigens in the rejection of transplanted myoblasts.
Myoblasts obtained from donors histoincompatible for several non-major histocompatibility complex antigens (i.e., including minor histocompatibility antigens) and from syngeneic donors were transplanted without any immunosuppression into the muscles of male dystrophic C57BL/10J mdx/mdx mice. Myoblasts from syngeneic mice resulted in the formation of a high percentage of dystrophin-positive fibers 16 weeks after the transplantation. There was no evidence of a cellular immune reaction against the donor myoblasts, i.e., no infiltration by CD4 or CD8 lymphocytes and no increased expression of granzyme B and interferon-gamma mRNAs. Transplantation of myoblasts obtained from donors histoincompatible only for non- major histocompatibility complex antigens produced a transient increase of dystrophin-positive fibers at 4 weeks after transplantation for some donor strains but not for others. For donor strains that did produce an increase at 4 weeks, the number of dystrophin-positive fibers was reduced 16 weeks after the transplantation. There was evidence of a cellular immune reaction-infiltration by CD4 and by CD8 lymphocytes and increased expression of granzyme B and interferon-gamma mRNAs. Transplantation of myoblasts obtained from male C57BL/10J +/+ mice into female C57BL/10J mdx/mdx mice also led to the presence of only a few dystrophin-positive fibers with the same signs of cellular immune reaction. In this later case, the cellular immune response was attributed to the H-Y minor antigens. Finally, antibodies against fetal calf serum were detected after both syngeneic and nonsyngeneic transplantations, indicating that the culture medium may also be a source of antigens. In mice, the presence of these antibodies against culture medium did not reduce the success of a first syngeneic transplantation.
Boulanger
A
A
Centre de Recherche en Neurobiologie, Hôpital de l'Enfant-Jésus, Québec, Canada.
Asselin
I
I
Roy
R
R
Tremblay
J P
JP
D000199:Actins / Q000096:biosynthesis; D000818:Animals; D000831:Animals, Newborn; D000917:Antibody Formation; D002478:Cells, Cultured; D005260:Female; D006084:Graft Rejection / Q000276:immunology*; D006649:Histocompatibility Antigens / Q000276:immunology*; D007111:Immunity, Cellular; D007371:Interferon-gamma / Q000096:biosynthesis; D007518:Isoantibodies / Q000096:biosynthesis; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008815:Mice, Inbred Strains; D018101:Mice, Inbred mdx; D018482:Muscle, Skeletal / Q000166:cytology* / Q000637:transplantation*; D009137:Muscular Dystrophy, Animal / Q000628:therapy*; D016133:Polymerase Chain Reaction; D014184:Transplantation, Homologous / Q000276:immunology* / Q000379:methods / Q000473:pathology; D014185:Transplantation, Isogeneic / Q000276:immunology* / Q000379:methods / Q000473:pathology
D000199:Actins; D006649:Histocompatibility Antigens; D007518:Isoantibodies; D007371:Interferon-gamma